Protalix Biotherapeutics, Inc. (NYSE:PLX) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Chuck Padala – Managing Director, Investor Relations
Celldex Therapeutics CLDX, +17.49% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset